Epirus Biopharmaceuticals (NASDAQ: EPRS) and Soligenix (NASDAQ:SNGX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Insider and Institutional Ownership

2.0% of Soligenix shares are held by institutional investors. 5.0% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Epirus Biopharmaceuticals and Soligenix’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Epirus Biopharmaceuticals N/A N/A N/A ($2.53) -0.06
Soligenix $6.98 million 1.88 -$6.76 million ($1.36) -1.68

Epirus Biopharmaceuticals has higher revenue, but lower earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Epirus Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Epirus Biopharmaceuticals and Soligenix, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epirus Biopharmaceuticals 0 0 0 0 N/A
Soligenix 0 0 2 0 3.00

Soligenix has a consensus target price of $8.00, suggesting a potential upside of 249.34%. Given Soligenix’s higher probable upside, analysts clearly believe Soligenix is more favorable than Epirus Biopharmaceuticals.

Profitability

This table compares Epirus Biopharmaceuticals and Soligenix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Epirus Biopharmaceuticals -2,025.65% -208.66% -97.67%
Soligenix -86.15% -129.88% -74.33%

Risk & Volatility

Epirus Biopharmaceuticals has a beta of 2.52, suggesting that its share price is 152% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 2.25, suggesting that its share price is 125% more volatile than the S&P 500.

Summary

Soligenix beats Epirus Biopharmaceuticals on 9 of the 10 factors compared between the two stocks.

Epirus Biopharmaceuticals Company Profile

EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.

Soligenix Company Profile

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive News & Stock Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related stocks with our FREE daily email newsletter.